The efficacy and safety of allopurinol in stable coronary heart disease patients with asymptomatic hyperuricemia
10.3760/cma.j.cn431274-20240905-01380
- VernacularTitle:别嘌醇应用于稳定性冠心病合并无症状性高尿酸血症患者的疗效及安全性
- Author:
Guixia SHI
1
;
Li SHEN
;
Jialu SHI
;
Ping LIU
;
Zhiyong QIAN
Author Information
1. 长沙卫生职业学院，长沙 410000
- Publication Type:Journal Article
- Keywords:
Allopurinol;
Stable coronary heart disease;
Asymptomatic hyperuricemia
- From:
Journal of Chinese Physician
2025;27(4):552-555
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of allopurinol in stable coronary heart disease patients with asymptomatic hyperuricemia (AH).Methods:Sixty stable coronary heart disease with AH patients admitted to the Changsha Third Hospital from January 2022 to December 2023 were selected. Patients were randomly divided into an observation group (allopurinol treatment group) and a control group (placebo group). The results of tablet exercise tests, treatment efficacy, blood uric acid levels, liver and kidney function indicators, and incidence of adverse events were compare and analyzed between two groups of patients.Results:The observation group had better exercise termination time, maximum ST descent time, and ST recovery time than the control group (all P<0.05). The total effective rate of the observation group after 6 weeks of treatment was significantly higher than that of the control group, and the difference was statistically significant (χ 2=5.455, P=0.02). There was no statistically significant difference in blood uric acid levels and liver and kidney function indicators between the two groups before treatment (all P>0.05). After treatment, both groups showed significant improvement in blood uric acid levels and liver and kidney function indicators compared to before treatment (all P<0.05). The levels of blood uric acid and liver and kidney function indicators in the observation group were significantly better than those in the control group after treatment (all P<0.05). The incidence of adverse events in the observation group during treatment was lower than that in the control group (χ 2=5.192, P=0.023). Conclusions:Allopurinol has a certain therapeutic effect on stable coronary heart disease with asymptomatic hyperuricemia, which helps patients enhance their physical activity and reduce the incidence of cardiovascular events.
